Alfredo Berruti, MD, University of Brescia, Brescia, Italy, talks on the rationale behind the Adjuvo trial investigating adjuvant therapy with mitotane in patients with adrenocortical carcinoma who are at low-intermediate risk of relapse following surgery. According to retrospective data, approximately 40-70% of patients with adrenocortical carcinoma will inevitably relapse following radical surgery. This produces a need for adjuvant therapy to reduce risk of relapse. The current guidelines follow that only those patients who have high-risk disease undergo adjuvant therapy, with uncertainties surrounding the use of adjuvant therapy in patients who are low-intermediate risk, which provided the rationale for the Adjuvo trial. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.